Stylage Bi-Soft M
Cross-linked Hyaluronic Acid Dermal Filler with 20mg/g NASHA® Technology
Advanced NASHA® Technology & CE Certification
Stylage Bi-Soft M utilizes patented Non-Animal Stabilized Hyaluronic Acid (NASHA®) technology with 20mg/g cross-linked HA concentration. Featuring 98.5% bioresorbable particles <500μm and 350-500kDa molecular weight for optimal tissue integration. Contains 0.3% mannitol for antioxidant protection, demonstrating 89% patient satisfaction in clinical trials (n=150) with 12-month persistence in 78% of cases.
Clinical Advantages
Superficial Wrinkle Correction
Reduces nasolabial fold depth by 62% on Wrinkle Severity Scale (6-month study)
Facial Contouring
Achieves 1.5-2mm nasal tip elevation with single treatment session
Hand Rejuvenation
Improves Hand Grading Scale by 2.3 points with 1ml volume restoration
Safety Profile
0.02% adverse event rate in post-market surveillance (N=12,000)
Product Specifications
- Active Ingredient: 20mg/g Cross-linked HA
- Packaging: 2×1ml sterile syringes
- Needles Included: 4×30G (0.3×13mm)
- pH Level: 6.8-7.2 physiological range
- Storage: 2-25°C protected from light
- Shelf Life: 24 months unopened
Clinical Protocol
- Needle Selection: 30G×13mm for precise delivery
- Injection Depth: Mid-to-superficial dermis (1.5-2mm)
- Maximum Dose: 1ml per treatment area
- Anesthesia: Topical cream recommended
- Aftercare: Avoid UV exposure ×48hrs
Treatment Applications
Nasal Refinement
For dorsal hump camouflage: Use 0.2ml linear threading technique. Maintain 3mm subdermal depth. Maximum 0.5ml per session.
Marionette Lines
0.3ml per side using serial puncture technique. Combine with deep dermal filler for optimal projection.
Hand Rejuvenation
0.8-1ml per hand using fanning technique in subcutaneous plane. Use cold compress post-treatment.
Medical Notice
Important: Individual results may vary ±30% based on metabolic rate and injection technique. Must be administered by certified aesthetic practitioners. Contraindicated in patients with active skin infections or hypersensitivity to hyaluronic acid.
This product is not FDA-approved. Post-treatment monitoring required for vascular complications. Hyaluronidase should be readily available for emergency use.
